PRINCIPAL INVESTIGATOR OF TRANSLATIONAL NEUROSCIENCES AND NEUROTHERAPEUTICS

Elmar Nurmemmedov

Ph.D., MBA

Director of Drug Discovery

Dr. Nurmemmedov’s research is focused on structural biology and drug discovery in the field of ‘challenging’ drug targets, particularly transcription factors. In the past several years, he has been trained in cancer biology and molecular pharmacology. During his training at Children’s Hospital Boston, Harvard Medical School, he led the drug discovery project at Broad Institute for sickle cell anemia. His training in molecular biophysics and molecular pharmacology contributed significantly to identification of early-stage drug candidates. The drug candidates that we developed have been out-licensed for preclinical development to industrial partners. At The Scripps Research Institute, Dr. Nurmemmedov successfully led drug discovery efforts for beta-catenin, a key regulator of colon cancer. Again, his deep knowledge of molecular pharmacology and protein interaction chemistry allowed me identify lead drug candidates, which are currently being developed for pre-clinical studies. Altogether, Dr. Nurmemmedov aims to continue his scientific career with molecular pharmacology and drug discovery applied especially in the field of glioblastoma.